Results 61 to 70 of about 3,587 (183)
Severe hyponatraemia to terlipressin treatment.
, 2013 Terlipressin is a vasopressin analogue. The clinical effect is attributable to affinity to vasopressin-1a receptors. However, it also has affinity to renal vasopressin-2 receptors, which can lead to water retention and dilutional hyponatraemia. We report
Poulsen, Anja +1 more
core +1 more source
Неотложная медицинская помощьAIM OF THE STUDY. Comparative clinical analysis of the efficacy of terlipressin and octreotide as additional drug therapy to mechanical hemostasis with nitinol stent in patients with liver cirrhosis complicated by bleeding from esophageal varices ...
A. Yu. Anisimov, Yu. A. Anisimov
doaj +1 more source
Trials, 2018 Background Transcervical resection of myoma or endometrium is a safe, hysteroscopic, minimally invasive procedure. However, intravasation of distension fluid is a common phenomenon during these procedures.
Lucilla E. Overdijk +5 more
doaj +1 more source
BMJ Paediatrics Open, 2021 Background The use of vasoactive agents like arginine vasopressin (AVP) and terlipressin to treat hypotension or persistent pulmonary hypertension in critically ill preterm neonates is increasing.
Samira Samiee-Zafarghandy +4 more
doaj +1 more source
The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
British Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +206 more
wiley +1 more source
Terlipressin versus other vasoactive drugs for hepatorenal syndrome [PDF]
, 2017 Background: Hepatorenal syndrome is defined as severe renal failure occurring in people with cirrhosis and ascites. Systematic reviews of randomised clinical trials found that, compared with placebo, terlipressin may reduce mortality and improve renal ...
Goldin, Alison H. +14 more
core +1 more source
In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2
Journal of Experimental Pharmacology, 2017 Khurram Jamil,1 Stephen Chris Pappas,2 Krishna R Devarakonda1 1Clinical Development, Mallinckrodt Pharmaceuticals, Bedminster, 2Orphan Therapeutics, LLC, Lebanon, NJ, USA Abstract: Terlipressin, a synthetic, systemic vasoconstrictor with selective ...
Jamil K, Pappas SC, Devarakonda KR
doaj
JGH Open, 2020 Background and Aim To explore the risk factors of hyponatremia caused by terlipressin. Methods Forty‐four patients with acute variceal bleeding treated with terlipressin from December 2016 to December 2018 were analyzed.
Xv Han +4 more
doaj +1 more source
The “dark” side of terlipressin: a case report of ischemic skin necrosis and review of literature
Egyptian Liver Journal, 2023 Background Terlipressin is a commonly used drug in cirrhotic patients with acute variceal bleed (AVB) due to its vasoconstrictor effects. Ischemic complications are uncommon adverse events associated with worse outcomes.
Arpit Shastri +4 more
doaj +1 more source
The FASEB Journal, Volume 39, Issue 17, 15 September 2025.The study involved patients who experienced acute kidney injury (AKI) following liver transplantation at the Third Affiliated Hospital of Sun Yat‐sen University from January 2015 to February 2023. Patients were categorized into CKD and non‐CKD groups based on their progression to chronic kidney disease (CKD) 3 months post‐surgery.
Liping Li +9 more
wiley +1 more source